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The modulation of host cell apoptosis by bacterial pathogens is of critical importance for the outcome of the infection
process. The capacity of Bartonella henselae and B. quintana to cause vascular tumor formation in immunocompro-
mised patients is linked to the inhibition of vascular endothelial cell (EC) apoptosis. Here, we show that translocation of
BepA, a type IV secretion (T4S) substrate, is necessary and sufficient to inhibit EC apoptosis. Ectopic expression in ECs
allowed mapping of the anti-apoptotic activity of BepA to the Bep intracellular delivery domain, which, as part of the
signal for T4S, is conserved in other T4S substrates. The anti-apoptotic activity appeared to be limited to BepA
orthologs of B. henselae and B. quintana and correlated with (i) protein localization to the host cell plasma membrane,
(ii) elevated levels of intracellular cyclic adenosine monophosphate (cAMP), and (iii) increased expression of cAMP-
responsive genes. The pharmacological elevation of cAMP levels protected ECs from apoptosis, indicating that BepA
mediates anti-apoptosis by heightening cAMP levels by a plasma membrane–associated mechanism. Finally, we
demonstrate that BepA mediates protection of ECs against apoptosis triggered by cytotoxic T lymphocytes, suggesting
a physiological context in which the anti-apoptotic activity of BepA contributes to tumor formation in the chronically
infected vascular endothelium.
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Introduction
Bacterial pathogens have developed various strategies to
subvert host cell functions to their beneﬁt. In particular,
intracellular bacteria have adapted mechanisms to modulate
the apoptotic pathway of their host cells [1]. The resulting
induction or inhibition of apoptosis is often crucial for a
successful infection of the host. Pathogen-induced apoptosis
can serve to eliminate key immune cells or to evade other
host defenses [1]. Several bacteria elicit an inﬂammatory
process by inducing a speciﬁc form of apoptotic cell death,
which at the place of infection leads to the disruption of
tissue barriers and thus may secure efﬁcient microbial spread
in the host [2,3]. In contrast, inhibition of apoptosis may be
essential for intracellular pathogens to establish chronic
infection. Pathogen-triggered anti-apoptosis of infected host
cells facilitates a slow microbial replication process and
enables persistence in the infected host. For example, the
obligate intracellular pathogen Chlamydia pneumoniae de-
grades—by an unknown effector mechanism—pro-apoptotic
BH-3 host cell proteins [4]. Rickettsia rickettsii protects invaded
host cells from apoptosis by activating a nuclear factor kappa
B (NFjB)–dependent survival pathway [5]. For many human
pathogens, the activation and inhibition of the apoptotic
machinery of the infected host cell thus has a central role
during the infection process [1].
The bacterial effectors known to modulate apoptosis are
mostly pro-apoptotic. The only described anti-apoptotic
effector is the outer membrane protein PorB of Neisseria
meningitidis [6]. PorB has been shown to interact with
mitochondria, where it is thought to block apoptosis by
preventing mitochondrial depolarization and cytochrome C
release. Interestingly, opposite effects were reported for the
PorB ortholog of N. gonorrhoea, which provokes a pro-
apoptotic effect upon interaction with mitochondria [7,8].
Bartonellae are facultative intracellular pathogens associ-
ated with the formation of vasoproliferative tumors in
humans (e.g., bacillary angiomatosis, bacillary peliosis, and
verruga peruana) [9]. These vascular lesions consist of an
increased number of endothelial cells (ECs), which are
colonized by extracellular and intracellular bacteria.
Although at least nine Bartonella species are known to infect
humans, vascular proliferation is mainly caused by the species
Bartonella henselae (Bh), B. quintana (Bq), and B. bacilliformis [9].
Upon EC infection in vitro, Bh and Bq are able to stimulate
proliferation and inhibition of apoptosis [9–11]. The anti-
apoptotic activity of bartonellae is considered to contribute
Editor: Pascale Cossart, Institut Pasteur, France
Received January 17, 2006; Accepted September 19, 2006; Published November
24, 2006
Copyright:  2006 Schmid et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author
and source are credited.
Abbreviations: aa, amino acids; AC, adenylate cyclase; Bh, Bartonella henselae; BID,
Bep intracellular delivery; Bq, Bartonella quintana; Bt, Bartonella tribocorum; Cya,
calmodulin-dependent adenylate cyclase; cAMP, cyclic adenosine monophosphate;
CFSE, carboxyfluorescein diacetate succinimidyl ester; CTL, cytotoxic T lymphocyte;
CRAfT, Cre-recombinase assay for translocation; EC, endothelial cell; FIC,
filamentation induced by cyclic adenosine monophosphate; GFP, green fluorescent
protein; HUVEC, human umbilical vein endothelial cell; IBMX, 3-isobityl-1-
methylxanthine; IL-8, interleukin 8; IPTG, isopropyl b-d-thiogalactosidase; MHC,
major histocompatibility complex; MOI, multiplicity of infection; NFjB, nuclear
factor kappa B; PI, propidium iodide; SD, standard deviation; T4S, type IV secretion;
WGA, wheat germ agglutinin
* To whom correspondence should be addressed. E-mail: christoph.dehio@
unibas.ch
PLoS Pathogens | www.plospathogens.org November 2006 | Volume 2 | Issue 11 | e1151083
synergistically to an unrelated mitogenic activity and results
in the formation of vascular tumors [10,11].
In Bh, inhibition of apoptosis is dependent on a functional
VirB/VirD4 system [12,13]. This type IV secretion (T4S)
system is a major virulence determinant for Bartonella–EC
interaction [12–14]. T4S systems are versatile transporters
ancestrally related to bacterial conjugation machines. Differ-
ent human pathogens have recruited such conjugation
machineries to inject macromolecular effectors across the
bacterial and host cell membranes directly into the host cell
cytosol, where they alter various cellular processes [15]. Bh
carries a pathogenicity island that encodes next to the virB/
virD4 locus seven putative T4S substrates, the Bartonella-
translocated effector proteins Bh BepA–G [13]. Deletion of
the pathogenicity island regions encoding bepA–G abolishes
the anti-apoptotic activity and all other VirB/VirD4-depend-
ent EC phenotypes [13]. However, the contribution of
individual Bh Beps to anti-apoptosis and the other cellular
phenotypes is unknown. All seven Bh Beps carry in their C-
terminus at least one conserved region, called the Bep
intracellular delivery (BID) domain [13]. The positively
charged C-terminal tail sequence together with the proximal
BID domain constitute a bipartite signal for T4S. Based on a
Cre-recombinase assay for translocation (CRAfT), this T4S
signal was shown to be functional for VirB/VirD4-dependent
transfer of four different Bh Beps (Bh BepB, Bh BepC, Bh
BepD, and Bh BepF) [13]. Evidence for translocation of Bh
BepA, Bh BepE, and Bh BepG is still missing.
Bh BepA, Bh BepB, and Bh BepC are paralogous proteins. A
Bh BepA ortholog is found in the animal pathogen B.
tribocorum (Bt) [16]. Remarkably, all BepA homologs encode
in their N-terminal part a conserved FIC (ﬁlamentation
induced by cyclic adenosine monophosphate [cAMP]) do-
main, which was proposed to be involved in bacterial cell
division [17], while the putative effector function within
human cells is unknown.
In this paper, we identify BepA as anti-apoptotic effector
of the vasoproliferative bartonellae Bh and Bq. We show that
this effector is translocated by the VirB/VirD4 system into
ECs. Further, we show that the anti-apoptotic activity is
conﬁned to the BID domain of Bh BepA, which also mediates
localization to the EC plasma membrane. We demonstrate
that Bh BepA provokes an elevation of intracellular cAMP
and the upregulation of cAMP-responsive genes, suggesting
that plasma membrane–associated Bh BepA triggers cAMP
production and signaling, resulting in the abrogation of
apoptotic processes. Accordingly, we were able to mimic the
anti-apoptotic effect of BepA by artiﬁcially increasing the
intracellular cAMP level in ECs. Finally, we demonstrate that
BepA can inhibit cytotoxic T lymphocyte (CTL)–mediated
apoptosis of ECs.
Results
Bh BepA Mediates Anti-Apoptosis in ECs
The anti-apoptotic activity of Bh on human umbilical vein
endothelial cells (HUVECs) requires a functional VirB/VirD4
system and at least one of the putatively secreted effectors Bh
BepA–G [12,13]. To identify the effector(s) required for
inhibition of apoptosis, we expressed them individually in the
substrate-free bepA–G mutant and assayed for anti-apoptotic
activity. To this end, HUVECs were infected with the
different Bh strains and apoptosis was induced by exposure
to actinomycin D. Morphological examination (Figure 1A),
measuring of caspase-3/-7 activity (Figure 1B), and ﬂow
cytometric analysis of Annexin V– and propidium iodide
(PI)–stained cells (Figure 1C) were used to monitor apoptosis.
DbepA–G did not display anti-apoptotic activity as reported
previously [13]. Strikingly, the expression of Bh BepA (by
plasmid pBh BepA) restored the anti-apoptotic activity to
wild-type level (Figure 1), whereas no other Bh Bep interfered
with actinomycin D–triggered apoptosis (unpublished data).
Consistently, strain DbepA carrying an in-frame deletion of
bepA did not protect HUVECs from apoptosis, whereas
complementation of this mutant with pBh BepA restored
the anti-apoptotic activity (Figure 1). To test for functionality
of the VirB/VirD4 system in the DbepA mutant, we monitored
the T4S-dependent process of invasome formation [12,18],
and furthermore quantiﬁed the translocation efﬁciency of a
reporter substrate (encoded by pRS51) using CRAfT [13].
Both assays conﬁrmed that the VirB/VirD4 T4S system is
functional in the DbepA strain (unpublished data).
Taken together, these results provide evidence that Bh
requires the putative T4S substrate Bh BepA to protect
HUVECs from apoptosis.
Bh BepA Is a VirB/VirD4 Substrate Translocated into ECs
CRAfT was used to demonstrate functionality of most of
the C-terminal bipartite T4S signals of Bh Beps [13], while this
assay was negative for the putative T4S substrate Bh BepA
(unpublished data). Here, we adapted the calmodulin-
dependent adenylate cyclase (Cya) reporter assay [19,20] as
an alternative to test for translocation of Bh BepA into
HUVECs. Translocation of a Cya reporter fusion is demon-
strated by the increase in the intracellular cAMP level. An N-
terminal FLAG-tag epitope was fused to Cya to determine the
stability of fusion proteins by immunoblot analysis (Figure 2A
and 2C). As positive control, the T4S signal of Bh BepD (Bh
BepD352–534) [13] was fused to the FLAG-Cya reporter
PLoS Pathogens | www.plospathogens.org November 2006 | Volume 2 | Issue 11 | e1151084
A Bacterial Protein Mediating Anti-Apoptosis
Synopsis
The capacity of infected host cells to die by apoptosis (programmed
cell death) is critical for controlling pathogen replication and
survival. Bacterial pathogens have thus developed strategies to
inhibit host cell apoptosis, allowing them to preserve their cellular
habitat during chronic infection. For instance, the capacity of the
facultative intracellular pathogen Bartonella henselae to trigger
tumor formation as a consequence of chronic infection of the
human vasculature is linked to the inhibition of endothelial cell
apoptosis. This study describes the identification and functional
characterization of the anti-apoptotic bacterial effector protein BepA
of B. henselae, which is shown to be sufficient to inhibit endothelial
cell apoptosis, i.e., as triggered by activated cytotoxic T lympho-
cytes. Upon translocation into endothelial cells via a bacterial type IV
secretion system, BepA localizes to the plasma membrane, where it
triggers the production of second messenger cyclic adenosine
monophosphate in quantities effective for blocking apoptosis.
Strikingly, the capacity of BepA to mediate membrane localization,
cyclic adenosine monophosphate production, and the resulting
inhibition of apoptosis is confined to a conserved domain that
originally evolved in bacteria as a signal for type IV secretion. This
study thus highlights the convergent evolution of an anti-apoptotic
effector protein of purely bacterial origin.
Figure 1. Bh BepA Meditates Inhibition of Apoptosis in ECs
(A and B) HUVECs were infected for 24 h with the indicated Bh strains (MOI¼ 300) or left uninfected for this period (control). If not indicated differently,
apoptosis was then triggered by the addition of actinomycin D. Then, 12 h later, (A) morphological changes were visualized by recording phase contrast
images (bar¼ 40 lm), and (B) caspase-3/-7 activities were determined with a specific fluorogenic peptide substrate. Arrowheads (A) indicate apoptotic
cells displaying membrane blebbing.
(C) Twenty-four hours after induction of apoptosis, the loss of membrane asymmetry was quantified by flow cytometric analysis of AlexaFluor488
Annexin V– and PI-stained cells, allowing us to quantify the rate of apoptotic cells (Annexin V–positive and PI-negative). Mean and standard deviation
(SD) are shown for one representative out of three independent replica experiments. All strains were tested a minimum of three times in triplicate
samples.
doi:10.1371/journal.ppat.0020115.g001
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(pFLAG-Cya–Bh BepD352–534). To test for translocation of Bh
BepA, either full-length protein (Bh BepA1–544) or the C-
terminal domain harboring the putative T4S signal (Bh
BepA305–544) was fused to FLAG-Cya. These reporter con-
structs were expressed either in Bh wild-type or in the DvirB4
mutant lacking a functional VirB/VirD4 system. HUVECs
infected with wild-type-expressing FLAG-Cya did not display
any signiﬁcant increase of the cAMP level compared with
wild-type without the pFLAG-Cya plasmid. In contrast,
FLAG-Cya fused to either Bh BepD352–534, Bh BepA1–544, or
Bh BepA305–544 resulted in an approximately 10-fold increase
of intracellular cAMP levels in HUVECs (Figure 2B). This
effect was dependent on a functional VirB/VirD4 system. In
summary, we show that BepA is a VirB/VirD4 substrate that
harbors a functional C-terminal T4S signal.
The BID Domain of Bh BepA Is Sufficient to Inhibit
Apoptosis
Next, we determined whether ectopic expression of Bh
BepA in HUVECs is sufﬁcient to mediate anti-apoptosis. N-
terminal green ﬂuorescent protein (GFP) fusions to full-
length Bh BepA or fragments thereof were constructed in an
appropriate eukaryotic expression vector. As control we
included the expression vector pGFP encoding just GFP
(Figure 3A). Then, 24 h after transfection of HUVECs with the
different GFP fusion constructs, cells were either exposed to
actinomycin D (apoptosis induction) or left untreated (non-
induced control) for another 12 h. Then, cells were stained
with Annexin V and PI, and the proportion of apoptotic cells
among the GFP-positive cell population was quantiﬁed by
ﬂow cytometry.
HUVECs transfected with pGFP and treated with actino-
mycin D displayed an apoptotic rate of 13% (Figure 3B).
Fusion of full-length Bh BepA to the C-terminus of GFP
(pGFP–Bh BepA1–544) reduced the apoptotic population
almost 4-fold to a level similar to that of the non-induced
control. The same anti-apoptotic activity was observed when
only the C-terminal bipartite T4S signal of Bh BepA was
fused, thus missing the ﬁrst 304 N-terminal amino acids
encoding the FIC domain (pGFP–Bh BepA305–544). In contrast,
fusion of the FIC domain (pGFP–Bh BepA1–304) did not result
in inhibition of apoptosis. Further analysis showed that
fusion of the BID domain (142 amino acids [aa]) to GFP
(pGFP–Bh BepA305–446) was sufﬁcient to inhibit apoptosis,
whereas fusion of the positively charged C-terminal tail plus
only part of the BID domain (pGFP–Bh BepA403–544) did not
result in anti-apoptosis (Figure 3B). Rather, expression of the
latter construct had a pro-apoptotic effect, as indicated by
Figure 2. Bh BepA Is a Genuine VirB/VirD4 T4S Substrate That Is
Translocated into ECs
(A) The bars indicate the parts of Bh BepA or Bh BepD that were fused to
Cya. These reporter fusions were used to monitor translocation via the
VirB/VirD4 system. All constructs contain an N-terminal FLAG epitope for
immunological detection of the encoded fusion protein.
(B) Quantification of the amount of intracellular cAMP in HUVECs
infected for 20 h with the indicated bacterial strains (MOI¼300). Isogenic
strains with a functional (wild-type) or non-functional (DvirB4) VirB/VirD4
T4S system were used to express the different Cya reporter constructs.
Mean and SD are shown for one representative out of three independent
replica experiments.
(C) Steady-state FLAG-Cya fusion protein levels of the indicated Bh strains
grown on IPTG-containing medium.
doi:10.1371/journal.ppat.0020115.g002
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the increased apoptotic cell population in the untreated
sample. Taken together, these data demonstrate that ectopic
expression of the BID domain as part of the bipartite T4S
signal of Bh BepA in ECs is sufﬁcient to mediate protection
against apoptosis.
Anti-Apoptotic Bh BepA Constructs Associate with the
Plasma Membrane
To test for the subcellular localization of Bh BepA in host
cells, the generated GFP fusions (Figure 3A) were ectopically
expressed in HEK293T cells for 24 h, followed by immuno-
cytochemical staining for the cell surface with Texas Red–
conjugated wheat germ agglutinin (WGA). Samples were
analyzed by confocal microscopy by taking images in the xy-
plane. To better distinguish between cytoplasmic and
membrane-associated localization, we also captured images
in an xz-plane (indicated in Figure 3C by dashed lines).
Ectopically expressed GFP localized to the cytoplasm of
HEK293T cells, whereas the GFP–Bh BepA1–544 fusion
localized to the plasma membrane (Figure 3C). Interestingly,
all fusion proteins with anti-apoptotic activity localized to the
plasma membrane, while those that did not confer protection
localized primarily to the cytoplasm.
Fractionation of post-nuclear extracts of the transfected
HEK293T cells by ultracentrifugation was used as an
independent biochemical assay for analyzing the membrane
or cytosolic localization of ectopically expressed GFP-BepA
fusions. The obtained data (Figure 3D) were in good agree-
ment with the microscopic analysis presented in Figure 3C,
except that construct pGFP–Bh BepA403–544 displayed both
cytosolic and membrane localization.
Taken together, these data suggest that association with the
plasma membrane is critical for the anti-apoptotic activity of
Bh BepA.
Only BepA Orthologs from Vasoproliferative Bartonella
Species Display Anti-Apoptotic Activity
To assess whether anti-apoptosis is a general feature of
BepA homologs, we tested the orthologs encoded by other
Bartonella species for this activity. Bq was previously shown to
cause vascular tumor formation, whereas Bt was never
associated with vascular lesions [9]. Consistent with these
observations, only Bh and Bq, but not Bt wild-type, were able
to block actinomycin D–triggered caspase-3/-7 activation in a
T4S-dependent manner (Figure 4A). In the genome sequence
of Bq, the bepA gene is annotated as a pseudogene [21]. Closer
inspection of the sequence revealed that because of an
internal stop codon and a downstream-located start codon in
frame, this bepA locus is split into two open reading frames (Bq
bepA1 and Bq bepA2). Bq bepA1 encodes a FIC domain, and Bq
bepA2 encodes a BID domain and the positively charged C-
terminal tail, the latter representing a putative T4S signal.
Comparison of the amino acid sequences of Bq BepA1 and Bq
BepA2 with Bh BepA revealed high similarity (59% and 63%,
respectively). We cloned Bt bepA and Bq bepA2 into expression
plasmids, which were introduced into DbepA–G (Figure 4B). As
controls we included the paralogs Bh bepB and Bh bepC, which
in the initial screening of Bh Beps were found to lack anti-
apoptotic activity (Figure 4B and unpublished data). HUVECs
were infected for 24 h with the different isogenic strains, and
subsequently apoptosis was induced by actinomycin D. Of the
tested BepA homologs, only Bh BepA and Bq BepA2 inhibited
actinomycin D–triggered caspase-3/-7 activation (Figure 4C).
These ﬁndings revealed that Bq bepA2 encodes an anti-
apoptotic effector. To assign Bq BepA2 as a novel T4S
substrate, we translocated a FLAG-Cya-BepA2 fusion from Bh
into HUVECs by the Cya reporter assay (unpublished data).
These results show that the anti-apoptotic activity of BepA is
conserved among two human pathogens with vasoprolifer-
ative capacity (Bh and Bq), but not in Bt, which has not been
associated with vasoproliferation. Moreover, these data
conﬁrm the localization of the anti-apoptotic activity to the
C-terminal region of BepA that composes a functional T4S
signal [13].
Inhibition of Apoptosis Correlates with an Increased
Intracellular cAMP Level
To identify potential survival pathways mediated by anti-
apoptotic BepA, we analyzed Affymetrix GeneChip data
obtained for the transcriptome of HUVECs infected with Bh
wild-type versus the DvirB4 mutant impaired in T4S (M.
Dehio, M. Schmid, M. Quebatte, and C. Dehio, unpublished
data). These data revealed a T4S-dependent upregulation of
the NFjB- and cAMP-dependent CREM/CREB regulons in
HUVECs. Both signaling pathways have been described to
mediate, among other functions, protection against apoptosis
[22–24].
We tested whether these pathways were activated by anti-
apoptotic BepA homologs. We monitored activation of the
NFjB pathway in infected HUVECs by measuring the release
of interleukin 8 (IL-8). Bh wild-type triggered an increased IL-
8 release compared with DbepA–G or the uninfected control.
In contrast, none of the BepA homologs expressed in DbepA–
G induced increased IL-8 secretion (Figure 5A). This ﬁnding
indicates that the survival mechanism triggered by anti-
apoptotic BepA homologs is independent from the activation
of the NFjB pathway triggered by wild-type bacteria.
Activation of the cAMP-dependent CREM/CREB pathway
was assayed by quantitative real-time PCR of two cAMP-
inducible genes, namely pde4B and crem [25,26]. Only strains
translocating anti-apoptotic BepA homologs were found to
induce the expression of these genes in a statistically
signiﬁcant manner (Figure 5B). By quantifying intracellular
cAMP upon infection of HUVECs by the various isogenic Bh
strains, we further demonstrated that anti-apoptotic BepA
homologs signiﬁcantly increase the intracellular cAMP level
(Figure 5C).
A Rise in Intracellular cAMP Results in Protection of ECs
against Apoptosis
Since translocation of anti-apoptotic BepA homologs
resulted in a rise of the intracellular cAMP level, we further
studied the role of cAMP in anti-apoptosis. The intracellular
cAMP level is regulated by adenylate cyclases (ACs) generat-
ing cAMP, and phosphodiesterases degrading cAMP [27,28].
To trigger a physiological rise of the cAMP level in ECs, we
activated ACs with forskolin and in parallel inhibited cAMP
degradation by adding the phosphodiesterase-inhibiting drug
3-isobityl-1-methylxanthine (IBMX) [29,30]. HUVECs were
infected with the substrate-free DbepA–G strain and with the
BepA-expressing strain DbepA–G/pBh BepA in the absence
and presence of forskolin/IBMX. Apoptosis was induced by
exposure to actinomycin D and monitored by measuring
caspase-3/-7 activity. By adding forskolin/IBMX we were able
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to reduce caspase-3/-7 activity in uninfected HUVECs and
cells infected with the DbepA–G strain to a level similar to that
found in cells infected with DbepA–G/pBh BepA. Interestingly,
the addition of forskolin/IBMX did not have an additive
protection effect in DbepA–G/pBh BepA–infected HUVECs
(Figure 6A). The same results were obtained by adding the
cell-permeable cAMP analog dibutyryl cAMP to the culture
medium (Figure 6B). From these data we conclude that a
moderately increased intracellular cAMP level, as triggered
by Bh BepA, is sufﬁcient to protect ECs against apoptosis.
The Role of Bh BepA in Evading CTL-Mediated Apoptosis
During colonization of the human endothelium, intra-
cellular Bh are hidden from antibody- and complement-
mediated immune responses [9]. However, the infected ECs
may be killed by CTLs [31]. To study a putative role of Bh
BepA in protecting ECs from CTL-mediated apoptosis, we
used a major histocompatibility complex (MHC) class I–
restricted CTL clone that kills HLA-A2-positive HUVECs
upon extracellular loading with a Y-chromosome-encoded,
male-speciﬁc minor histocompatibility Ag peptide with the
sequence FIDSYICQV (SMCY peptide) [32]. To speciﬁcally
measure the rate of EC apoptosis without interference by
apoptotic CTLs, we pre-labeled the EC population with the
ﬂuorogenic dye CSFE. Pre-labeled HUVECs were left unin-
fected (control), or infected with wild-type, DbepA–G, or
DbepA–G/pBh BepA. Then, 24 h after infection, HUVECs were
either pre-loaded for 30 min with the CTL-stimulating SMCY
peptide (105 M) or not pre-loaded. After washing, CTLs were
added in an effector-to-target cell ratio of 5:1. At different
time points (0 h, 2.5 h, and 6 h), Annexin V and PI staining
was performed to quantify the amount of apoptotic HUVECs
(CSFE-positive, Annexin V–positive, and PI-negative) (Figure
7A and 7B). SMCY-treated HUVECs, which were either
uninfected or pre-infected with the BepA-deﬁcient DbepA–G
mutant strain, displayed a time-dependent increase in the
apoptotic population in comparison with respective control
cells without pre-loading of the CTL-activating SMCY
peptide. In sharp contrast, SMCY-treated HUVECs pre-
infected with wild-type or the BepA-expressing strain
DbepA–G/pBh BepA did not display any signiﬁcant increase
of apoptosis over control cells without pre-loading with the
SMCY peptide. These data indicate that BepA is capable of
protecting ECs against the MHC class I–restricted apoptotic
activity of CTLs. Consistently, we noticed that BepA-express-
ing bacteria, as well as the ectopic expression of a GFP–Bh
BepA fusion protein alone, protected ECs against cell death
triggered by a different CTL clone, which was activated by
phytohemagglutinin in an MHC class I–independent manner
(unpublished data). Together, these data indicate that trans-
located Bh BepA can effectively protect the chronically
infected vascular endothelium against CTL-mediated cell
death.
Discussion
The modulation of host cell apoptosis is a recurrent theme
in bacterial pathogenesis [1]. Research in this area focused
initially on the pro-apoptotic mechanisms triggered by
pathogens that typically cause acute infections (e.g., Shigella,
Salmonella, and Yersinia species). Some pro-apoptotic effectors
and their targeted cellular pathways have been studied in
molecular detail [33,34]. More recently, pathogen-triggered
anti-apoptosis was recognized as an important virulence trait
of bacteria that predominately cause chronic infection (e.g.,
Bartonella, Brucella, Chlamydia, Helicobacter, Mycobacterium, and
Rickettsia species) and thus need to protect their cellular
habitats by suppressing host-triggered apoptosis [35]. How-
ever, the bacterial effectors, and to a large extent also the
cellular pathways involved in mediating pathogen-induced
anti-apoptosis, remain poorly deﬁned. In the case of Bh and
Bq, the formation of vascular tumors in immunocompro-
mised patients was shown to be linked to the inhibition of
apoptosis of infected ECs [10]. In this report, we identiﬁed the
anti-apoptotic factor of these vasoproliferative bartonellae.
Deletion of the Bh bepA gene resulted in the complete loss of
the anti-apoptotic activity of Bh, whereas expression of Bh
bepA in trans restored the activity to wild-type level. Bh BepA
was previously described as a putative substrate of the T4S
system VirB/VirD4 [13]; we used the Cya reporter assay to
demonstrate that Bh BepA is indeed translocated into ECs in
a T4S-dependent manner. Bh BepA is thus a genuine T4S
effector that inhibits apoptosis upon translocation into
HUVECs. It is worth noting that we have been unable to
show translocation of Bh BepA by CRAfT, an assay that we
previously used to demonstrate translocation of several other
Bh Beps [13]. Nuclear import of the Cre reporter protein
fusion is a prerequisite for a positive readout by CRAfT [13],
suggesting that the negative readout obtained for Bh BepA
fusions could result from protein recruitment to an intra-
cellular localization that interferes with nuclear import.
Indeed, ectopic expression of full-length Bh BepA fused to
GFP revealed a prominent localization of the fusion protein
to the plasma membrane, in contrast to the cytosolic
localization of GFP alone. Unlike ectopically expressed GFP,
the GFP–Bh BepA fusion also conferred protection against
EC apoptosis. These data demonstrate that Bh BepA is not
only required but also sufﬁcient for inhibiting EC apoptosis,
Figure 3. Delineation and Subcellular Localization of the Region of Bh BepA Required for Inhibition of Apoptosis
(A) Schematic presentation of N-terminal GFP fusions to parts of Bh BepA.
(B) Determination of apoptosis following ectopic expression of the constructs illustrated in (A). GFP-BepA fusion proteins were ectopically expressed in
HUVECs for 24 h, followed by 12 h incubation in the presence or absence of actinomycin D as indicated. The loss of membrane asymmetry in
transfected cells (GFP-positive) was then quantified by flow cytometric analysis of APC-Annexin V– and PI-stained cells, allowing us to quantify the rate
of apoptotic cells (Annexin V–positive and PI-negative). The means and SD of three independent replica experiments are shown. The p-values were
determined by using an unpaired Student’s t-test.
(C) The GFP–Bh BepA fusion proteins illustrated in (A) were ectopically expressed for 24 h in HEK293T cells. Cells were immunochemically stained to
label the cell surface with Texas Red–conjugated WGA. Confocal pictures were taken for GFP (green channel) and WGA (red channel) in the xy-plane
(upper image, overlay both channels, bar ¼ 10 lm), and also in the xz-plane at the dashed stroke line (lower images, single channels and overlay
channels).
(D) Fractionation of GFP–Bh BepA fusion proteins into membrane and cytosolic fractions by ultracentrifugation of post-nuclear extracts harvested from
transfected HEK293T cells.
doi:10.1371/journal.ppat.0020115.g003
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Figure 4. Comparison of the Anti-Apoptotic Activities of BepA Homologs
(A) Anti-apoptotic activities of wild-type and isogenic DvirB4 mutant
strains of Bh in comparison with Bq and Bt.
(B) Domain structure of Bh BepA, its paralogs Bh BepB and Bh BepC, and
the orthologs Bt BepA and Bq BepA1/Bq BepA2. These homologs contain
conserved FIC and BID domains in their N-terminal and C-terminal
regions, respectively, except for Bq, where the orthologous locus is split
between these domains into two separate open reading frames by an
internal stop codon.
(C) Anti-apoptotic activity of BepA homologs. HUVECs were infected with
the indicated Bh strains for 24 h, followed by apoptotic induction with
actinomycin D for 12 h. Caspase-3/-7 activities were then determined
with a specific fluorogenic peptide substrate. Mean and SD are illustrated
for one representative out of three independent experiments.
doi:10.1371/journal.ppat.0020115.g004
Figure 5. Anti-Apoptotic BepA Homologs Mediate an Increase in
Intracellular cAMP and an Upregulation of cAMP Response Genes
HUVECs were infected with the indicated Bh strains. The means and SD
of one out of three independent replica experiments performed in
triplicate samples are presented.
(A) IL-8 was determined in culture supernatants after infection for 54 h
with MOI¼ 300.
(B) Expression of the cAMP-responsive genes pde4B and crem was
determined by quantitative real-time PCR after infection for 54 h with
MOI¼ 300.
(C) Intracellular cAMP levels were determined after infection for 30 h with
MOI¼ 150.
In (B) and (C), samples marked with an asterisk (p , 0.05) differ
statistically significantly from DbepA–G using an unpaired Student’s t-
test.
doi:10.1371/journal.ppat.0020115.g005
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and that this anti-apoptotic effector localizes to the plasma
membrane. Moreover, ectopic expression of various parts of
Bh BepA fused to GFP revealed a strict correlation of the
capacity to mediate anti-apoptosis with localization to the
plasma membrane (as opposed to the primarily cytoplasmic
localization of fusions that did not cause anti-apoptosis). This
ﬁnding indicates that plasma membrane targeting may be
important for the anti-apoptotic activity of Bh BepA.
In search of the cellular pathway by which Bh BepA
mediates anti-apoptosis in ECs, we ﬁrst tested whether an
NFjB-dependent survival pathway is involved. The anti-
apoptotic activity of R. rickettsii in ECs was reported to
depend on NFjB activation [5], and we have previously shown
that Bh activates NFjB in a VirB/VirD4- and Bep-dependent
manner [13]. Here, we demonstrated that Bh BepA alone does
not trigger the NFjB-dependent secretion of IL-8; even so, it
fully protects against apoptosis. Thus, NFjB does not seem
critical for Bh BepA–mediated anti-apoptosis. Affymetrix
GeneChip experiments indicated that Bh also triggers a cAMP
signaling pathway in a T4S-dependent manner (M. Dehio, M.
Schmid, M. Quebatte, and C. Dehio, unpublished data). Here,
we have shown that the anti-apoptotic activity of Bh BepA in
HUVECs correlates with elevation of the intracellular cAMP
level and results in the upregulation of cAMP-stimulated gene
expression. Recently, it emerged that the regulation of
apoptosis is an important facet of cAMP signal transduction
[30,36–38]. Moderately elevated cAMP levels were reported to
protect several cell types against apoptosis, while the survival
mechanisms differed from cell type to cell type and were
considered to require the activation of protein kinase A,
extracellular signal regulated, mitogen-activated protein
kinase, or guanine nucleotide exchange factor signaling
pathways, which subsequently resulted in the expression of
anti-apoptotic genes [23,36,37,39–44]. In our system, the
speciﬁc downstream signaling pathway mediating cAMP-
dependent anti-apoptotis remains elusive: efforts to block
putatively involved signaling molecules (i.e., protein kinase A)
failed because of apparent cytotoxic effects of effective
inhibitor concentrations during the extended time frame of
the apoptosis assay.
Importantly, a physiological rise in the intracellular cAMP
level has been reported to fully protect ECs against apoptosis
[45]. Consistent with this, we observed that increased cAMP
levels caused by the combined action of the AC-activating
drug forskolin and the phosphodiesterase-inhibiting drug
IBMX resulted in a complete suppression of actinomycin D–
induced apoptosis in HUVECs. Forskolin/IBMX-treated cells
displayed an increase in the expression of cAMP-regulated
genes similar to that observed upon infection with anti-
apoptotic Bh strains. cAMP is produced in eukaryotic cells by
the family of membrane-anchored ACs. ACs are activated by
heterotrimeric G proteins that are regulated by G protein–
coupled receptors [46]. Since the anti-apoptotic activity of Bh
BepA in HUVECs is strictly associated with the plasma
membrane localization of this effector, concomitant with an
increase in the cAMP level, we propose that Bh BepA may
trigger anti-apoptosis by interacting either with ACs directly,
or with plasma membrane–associated heterotrimeric G
proteins or G protein–coupled receptors that regulate AC
activity.
Ectopic expression of GFP fusions with different parts of
Bh BepA conﬁned the anti-apoptotic activity to a region of
142 aa, which corresponds to the BID domain. This conserved
domain was previously shown to be present in a least one
copy in all Beps of Bh and Bq [13,14,21]. The BID domain plus
the C-terminal positively charged tail sequence of the Beps
was shown to constitute a bipartite translocation signal for
T4S [13]. Interestingly, in contrast to the BID domain of Bh
BepA, the conserved BID domains of the paralogs Bh BepB
and Bh BepC have not been associated with anti-apoptosis.
This indicates that subsequent to the expansion of this
paralogous protein family by gene duplication, the Bh BepA
BID domain acquired, in addition to its crucial function as a
signal for T4S, the capacity to mediate anti-apoptosis. How
this rather short domain may mediate these unrelated
activities is presently unknown. It may be speculated that
the BID domain represents a basic fold that mediates a
protein–protein interaction with the T4S machinery that is
crucial for protein translocation, and that in Bh BepA this
basic fold is adapted to also mediate speciﬁc interaction with
the plasma membrane–associated, cAMP-generating signaling
cascade of ECs.
Each of the paralogs Bh BepA, Bh BepB, and Bh BepC
carries in the N-terminal region one copy of the FIC domain.
While this conserved domain of unknown function might be
Figure 6. A Pharmacologically Increased cAMP Level in ECs Mimics the
Anti-Apoptotic Effect of Bh BepA
HUVECs were infected for 24 h with the indicated Bh strains or left
uninfected (control) in the absence or presence of either (A) forskolin (1
lM) and IBMX (10 lM) or (B) dibutyryl cAMP (1 mM). If indicated,
apoptosis was then induced with actinomycin D. Caspase-3/-7 activities
were determined 9 h later. All strains were tested in triplicates a
minimum of three times.
doi:10.1371/journal.ppat.0020115.g006
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important for the effector function of Bh BepB and Bh BepC,
our results demonstrate that the FIC domain is dispensable
for the anti-apoptotic activity of Bh BepA. Interestingly, an
internal stop codon and downstream-located start codon
within the bepA ortholog of Bq split this locus into two
separate open reading frames (Bq bepA1 and Bq bepA2). Bq
BepA1 has the FIC domain but lacks a T4S signal, and thus
cannot be translocated into ECs. In contrast, Bq BepA2
consists only of the T4S signal, which we have shown mediates
both T4S-dependent translocation and anti-apoptosis in ECs.
It thus appears plausible that the functional diversiﬁcation of
BepA into an anti-apoptotic effector occurred in the
common ancestor of the closely related species Bh and Bq
[21], and that following speciation the acquisition of addi-
tional mutations resulted in the elimination of the dispen-
sable N-terminal FIC domain in Bq.
Interestingly, unlike Bh BepA and Bq BepA2, the BepA
ortholog of Bt does not mediate any anti-apoptotic activity,
nor any measurable activation of the cAMP pathway. This
observation is in agreement with the previously reported
ﬁnding that, among the bartonellae, the anti-apoptotic
activity is limited to the vasoproliferative species Bh and Bq
[10].
To asses if the here identiﬁed anti-apoptotic activity of Bh
BepA might be able to protect the cellular habitat of Bh
during the infection process, we used a co-culture system of
HUVECs with human CTLs. CTLs execute cell-mediated
immunity, an immune mechanism probably involved in the
elimination of Bh infection [9,12,47]. Cell-mediated immunity
particularly serves as a defense mechanism against microbes
that survive and replicate inside infected host cells. Upon
recognition of MHC class I–displaying microbial peptides,
CTLs are activated to kill their target cells by the release of
perforin and granzymes [31,48]. Perforin forms pores in the
target cell membrane and assists the delivery of pan-caspase-
activating granzymes into the cytoplasm of the target cell
[44,49,50]. In our study, we used a CTL clone that is activated
in an MHC class I–restricted manner by extracellular loading
of HLA-A2-positive HUVECs with an HLA-A2-speciﬁc pep-
tide (SMCY). Such activated CTLs kill their target cells in a
perforin-dependent manner [32], primarily by triggering
granzyme-dependent apoptosis [50,51]. Bh BepA–expressing
strains indeed inhibited CTL-triggered EC apoptosis, indicat-
ing that the biological function of Bh BepA expression in vivo
might be to protect the integrity of its colonized cellular
niche. The Bh BepA–mediated resistance of ECs to CTL-
dependent cell death points towards an important role of
BepA in escaping cell-mediated immunity and thus in
protecting the integrity of the chronically infected vascula-
ture, which is a prerequisite for vascular proliferation. The
establishment of an animal model for Bartonella-triggered
vasoproliferation now appears an urgent need for studying
the precise contribution of BepA-mediated anti-apoptosis in
the process of vascular tumor formation.
In summary, the anti-apoptotic T4S effectors Bh BepA and
Bq BepA2 characterized in this study represent striking
examples of the evolution of new pathogenic traits in
bacteria. The delineation of their anti-apoptotic activity to
the conserved BID domain, and their proposed role in
maintaining the cellular habitat by mediating anti-apoptosis
via speciﬁc interaction with the plasma membrane–associ-
ated, cAMP-generating signaling cascade of ECs, should pave
the way for future studies to elucidate the molecular and
structural basis of Bartonella-mediated anti-apoptosis in the
vascular endothelium and the role of this pathological
process in vasoproliferative tumor growth.
Materials and Methods
Bacterial strains and growth conditions. The bacterial strains used
in this study are listed in Table 1. Bartonella spp. were grown on
Columbia agar plates containing 5% deﬁbrinated sheep blood (CBA
plates) at 35 8C and 5% CO2 for 2–4 d. Strain RSE247, a spontaneous
streptomycin-resistant strain of Bh ATCC 49882T [12], served as wild-
type in this study. When indicated, media were supplemented with 30
lg/ml kanamycin, 100 lg/ml streptomycin, 12.5 lg/ml gentamicin,
and/or 500 lM isopropyl b-D-thiogalactosidase (IPTG). Escherichia coli
strains were cultivated in Luria-Bertani liquid medium, or after
addition of agar on plates, at 37 8C overnight. When indicated, media
were supplemented with 50 lg/ml kanamycin, 200 lg/ml ampicillin, 25
lg/ml gentamicin, 500 lM IPTG, and/or 1 mM diaminopimelic acid.
DNA manipulation. Plasmids used in this study are listed in Table
1. Primers are listed in Table 2.
Plasmids for in-frame deletions and complementation of deletion
mutants were constructed as follows: pMS5 used for creating the
DbepA mutant was already described before [13]. The use of pMS5 for
gene replacement in RSE247 resulted in the DbepA mutant MSE154.
Plasmid pRS63, used for generating a DvirB4 in-frame deletion
mutant in Bq, was constructed as follows. The BamHI insert of pRS14
[16] was replaced by a 1,318-bp BamHI fragment of the Bq virB locus
containing a 2,112-bp in-frame deletion in virB4. This fragment was
constructed by megaprime PCR from two PCR products. Product 1
(0.75 kb) was ampliﬁed with primers prRS226 and prRS227 and
contained the ﬁrst 115 bp of the virB4 gene and upstream sequences.
Product 2 (0.55 kb) was ampliﬁed with primers prRS228 and prRS229
and contained the last 120 bp of the virB4 gene and downstream
sequences. Megapriming and PCR ampliﬁcation with primers
prRS226 and prRS229 were performed as described [16].
Plasmids for complementation of DbepA mutant and DbepA–G
mutant were constructed as follows: For constructing vectors
expressing N-terminal FLAG-tagged Bep proteins, the plasmid
pPG100 was used. The fragments were generated by PCR ampliﬁca-
tion from chromosomal DNA of RSE247 and Bt, using oligonucleo-
tide primers prPG92/93, prPG95/129, prPG97/130, or pMS27/28, and
were inserted by the ﬂanking NdeI site into the corresponding site of
pPG100, resulting in pPG101 (encoding Bh BepA), pMS006 (encoding
Bh BepB), pMS007 (encoding Bh BepC), and pMS011 (encoding Bt
BepA). To construct plasmid pMS100, carrying a multiple cloning
site, prGS01 and prGS02 were annealed together and the resulting
45-bp fragment was inserted into pPG100 using the NdeI site. Using
oligonucleotide primers pMS102 and prMS103, a fragment of 0.85 kb
was ampliﬁed using chromosomal DNA of Bq as template. Then, using
SalI/XmaI sites, this fragment was inserted into the corresponding site
of pMS100, giving rise to pMS106. Plasmid pMS105 was constructed
as follows: using ﬂanking SalI/XmaI sites, the 1.65-kb PCR fragment
Figure 7. Bh BepA Protects ECs against CTL-Mediated Cell Death
Confluent HUVEC monolayers fluorescently labeled with the cell-tracking dye CFSE were infected with the indicated bacterial strains for 24 h or left
uninfected (control). Then cells were incubated in the presence (þ SMCY) or absence ( SMCY) of SMCY peptides, followed by washing. CTLs were
added in an effector-to-target cell ratio of 5:1 for the indicated period, and after washing and Annexin V– and PI-staining, the apoptotic cell population
of HUVECs was determined by flow cytometry analysis (CFSE-positive, Annexin V–positive, and PI-negative).
(A) Dot plots are shown for representative samples.
(B) Summary graph representing HUVEC apoptosis during CTL co-culture. The mean and SD of one of two independent experiments performed in
duplicates is shown.
doi:10.1371/journal.ppat.0020115.g007
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Table 1. Bacterial Strains and Plasmids Used in This Study
Strain or Plasmid Name Genotype or Relevant Characteristics Reference or Source
Bh strains ATCC 49882T Houston-1, isolated from a bacteremic HIV patient [57]
MSE150 DbepA–G mutant of RSE247 [13]
MSE154 DbepA mutant of RSE247 This work
MSE156 MSE150 containing pPG101 This work
MSE159 MSE150 containing pMS007 This work
MSE162 MSE150 containing pRS51 [13]
MSE164 MSE154 containing pRS51 This work
MSE166 MSE154 containing pPG101 This work
MSE167 MSE150 containing pMS006 This work
MSE175 MSE150 containing pMS011 This work
MSE218 MSE150 containing pMS100-A This work
MSE220 MSE150 containing pMS100-D This work
MSE226 MSE150 containing pMS100-B This work
MSE228 MSE150 containing pMS100-C This work
MSE240 MSE150 containing pMS102 This work
MSE242 MSE150 containing pMS104 This work
MSE249 RSE247 containing pMS400 This work
MSE251 RSE247 containing pMS401 This work
MSE253 RSE247 containing pMS404 This work
MSE255 RSE242 containing pMS400 This work
MSE257 RSE242 containing pMS401 This work
MSE259 RSE242 containing pMS404 This work
MSE269 MSE150 containing pMS106 This work
MSE273 RSE247 containing pMS406 This work
MSE275 RSE242 containing pMS406 This work
MSE277 RSE247 containing pMS405 This work
MSE279 RSE242 containing pMS405 This work
RSE232 RSE242 containing pRS51 [13]
RSE242 DvirB4 mutant of RSE247 [12]
RSE247 Spontaneous Smr strain of ATCC 49882T, serving as wild-type [12]
RSE308 RSE247 containing pRS51 [13]
Bq strains JK-31 Isolated from a bacteremic patient with bacillary angiomatosis [58]
RSE356 Spontaneous Smr strain of JK-31, serving as wild-type This work
RSE569 DvirB4 mutant of RSE356 This work
VR 358 [58]
Bt strains IBS 506T Isolated from a brown rat (Rattus norvegicus) (CIP 105476T) [16]
RSE149 Spontaneous Smr strain of IBS 506T, serving as wild-type [16]
RSE173 DvirB4 mutant of RSE149 [16]
E. coli strains b2150 F’ lacZDM15 lacIq traD36 proAþBþ thrB1004 pro thi strA hsdS lacZDM15
DdapA::erm (ErmR) pir
[16]
NovaBlue endA1 hsdR17(r K12–m K12þ) supE44 thi-1 recA1 gyrA96 relA1 lac[F9 proAþBþ la-
cIqZDM15::Tn10 (TcR)]
Novagen, Madison
Plasmids pPG100 E. coli– Bartonella spp. shuttle vector, encoding a short FLAG epitope [13]
pPG101 Derivative of pPG100, encoding FLAG::Bh BepA This work
pRS40 Cre vector encoding NLS::Cre [13]
pRS48 Cre vector containing NLS::Cre::Bh BepA (aa 305–544) This work
pRS49 Cre vector encoding NLS::Cre::Bh BepB (aa 303–542) [13]
pRS50 Cre vector encoding NLS::Cre::Bh BepC (aa 292–532) [13]
pRS51 Cre vector encoding NLS::Cre::Bh BepD (aa 352–534) [13]
pRS55 Cre vector encoding NLS::Cre::Bt BepA (aa 326–568) This work
pMS005 Mutagenesis vector for generating a DbepA in-frame deletion in Bh [13]
pMS006 Derivative of pPG100, encoding FLAG::Bh BepB This work
pMS007 Derivative of pPG100, encoding FLAG::Bh BepC This work
pMS013 Cre vector containing NLS::Cre::Bh BepA (aa 1–544) This work
pMS011 Derivate of pPG100, encoding FLAG::Bt BepA This work
pMS100 Insertion of a multiple cloning site into pPG100 This work
pMS106 Derivate of pMS100, encoding FLAG::Bq BepA2 This work
pMS100-A Derivate of pMS100, encoding FLAG::Bh BepA (aa 305–542) This work
pMS100-B Derivate of pMS100, encoding FLAG::Bh BepB (aa 303–542) This work
pMS100-C Derivate of pMS100, encoding FLAG::Bh BepC (aa 292–542) This work
pMS100-D Derivate of pMS100, encoding FLAG::Bh BepD (aa 352–534) This work
pMS105 Insertion of Bh BepA into pMS100 This work
pMS111 Containing the hybrid yopE-cyaA gene [19]
pMS400 pMS100 containing a 1.23-kb PCR fragment carrying the cya of Bordetella pertus-
sis (amplified from pMS111-Cornelis)
This work
pMS401 Cya vector encoding Bh BepA (aa 305–542) This work
pMS404 Cya vector encoding Bh BepD (aa 252–534) This work
pMS405 Cya vector encoding Bh BepA This work
pMS406 Cya vector encoding Bq BepA2 This work
doi:10.1371/journal.ppat.0020115.t001
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generated by prMS37/38 (chromosomal DNA of RSE247 serves as a
template) was inserted into the corresponding sites in pRS40, yielding
pMS13. Using ﬂanking SalI/XmaI sites, the 1.65-kb fragment was
shuttled into the SalI/XmaI sites of pMS100. Using oligonucleotide
primers prRS167/180 and prRS187/188, fragments of 0.73-kb size
were ampliﬁed using chromosomal DNA of RSE247 and of Bt,
respectively, as template. Using ﬂanking SalI/XmaI sites, the frag-
ments were inserted into the corresponding site of pRS40, giving rise
to pRS48 and RS55, respectively. C-terminal sequences of the
different Bep proteins were shuttled into pMS100 using the ﬂanking
SalI/XmaI sites. The plasmids resulting from this step are given below,
as well as the range of amino acids of a given Bep protein fused to the
N-terminal FLAG: pMS100-A (shuttled from pRS48, aa 305–544 of Bh
BepA), pMS100-B (shuttled from pRS49, aa 303–542 of Bh BepB),
pMS100-C (shuttled from pRS50, aa 292–532), and pMS100-D
(shuttled from pRS51, aa 352–534 of Bh BepD).
Plasmids for expression of Cya-Bep fusion proteins were con-
structed as follows: To construct pMS400, the cya of pMS111 was PCR-
ampliﬁed with oligonucleotide primers prMS78/90 introducing a start
and a stop codon to the resulting cya fragment. Using ﬂanking NdeI/
XmaI sites, the 1.23-kb fragment was inserted in the corresponding
sites of pMS100. Plasmid pMS401 was derived by insertion of a 1.2-kb
NdeI/StuI fragment of pMS400, which includes the cya gene without
stop codon, into the corresponding sites of pMS100-A. The NdeI/StuI
fragment of pMS400 was further inserted in the corresponding site of
pMS100-D and pMS105, giving rise to pMS404 and pMS405,
respectively. To construct pMS406, Bq BepA2 was PCR-ampliﬁed
from chromosomal DNA of Bq with oligonucleotide primers
prMS103/104. Using ﬂanking PmeI/XmaI sites, the 0.86-kb fragment
was inserted in the StuI/XmaI sites of pMS400.
Plasmids for ectopic expression of GFP-BepA fusion proteins were
constructed as follows: To construct eGFP-Bep fusion proteins (see
Figure 4A), pWAY21 (Molecular Motion Lab, http://momotion.cn-
s.montana.edu), a CMV-driven EGFP for C-terminal fusion, was used
as basic vector. The plasmids resulting from this step and the
oligonucleotide primers used (with incorporated XmaI/XbaI sites
used for cloning to the corresponding sites of pWAY21) are given
below, as well as the range of amino acids of a given Bep protein fused
to eGFP: pMS21 (primers prMS68/69, aa 1–544 of Bh BepA), pMS22
(primer prMS76/77, aa 302–542 of Bh BepB), pMS23 (primers prMS83/
69, aa 305–544 of Bh BepA), pMS24 (primers prMS83/84, aa 305–446
of Bh BepA), pMS25 (primers prMS74/69, aa 403–544 of Bh BepA),
pMS26 (primers prMS68/75, aa 1–304 of Bh BepA), and pMS27
(primers prMS105/106, aa 1–277 of Bq BepA2).
The integrity of all constructs was conﬁrmed by sequence analysis
and Western blotting using anti-FLAG M2 antibodies (Sigma-Aldrich,
http://www.sigmaaldrich.com).
Generation of deletion mutants. pRS63 was used to generate the
DvirB4 mutant RSE569 in the RSE356 background as previously
described for Bt [16]. The spontaneous streptomycin-resistant mutant
RSE356 was obtained by selection of B. quintana JK-31 on 100 mg/l
streptomycin.
Cell lines and cell culture. HUVECs were isolated as described [18].
HUVECs and the human embryonic kidney cell line HEK293T were
cultured as described before [12]. The stable transfected endothelial
cell line Ea.hy296/pRS56-c#B1 was cultured as reported [13].
Infection assay. HUVECs (passage 3–7) were plated as described
before [12]. Unless stated differently, cells were infected with a
multiplicity of infection (MOI) of 300 bacteria per cell [10] in M199/
10% FCS/500 lM IPTG and incubated for the indicated time. If
speciﬁed, 100 nM actinomycin D (Sigma-Aldrich) was added to trigger
apoptosis as described before [10,12].
Table 2. Oligonucleotide Primers Used in This Study
Name Sequencea Restriction Site
prCREMfw ATCGCCCGGAAGTTTGC
prCREMrv CAGCTCTCGTTTGCGTGTTG
prGAPDHfw GAAGGTGAAGGTCGGAGTC
prGAPDHrv GAAGATGGT GATGGGATTTC
prGS001 TATGAAGGCCTCGAGTCGACCGCGGCCGCATCGATGACCCGGG
(NdeI/StuI/XhoI/SalI/SacII/NotI/ClaI/XmaI)
prGS002 TACCCGGGTCATCGATGCGGCCGCGGTCGACTCGAGGCCTTCA
(XmaI/ClaI/NotI/SacII/SalI/XhoI/StuI/NdeI)
prMS027 CGGGAATTCCATATGCAAAAGGGAATATTTCACT NdeI
prMS028 CGGGAATTCCATATGTTAGCTGGCTATAGCGAGTA NdeI
prMS037 ACGCGTCGACCTCCAAAGGCAAAAGCAAAAACG SalI
prMS038 TCCCCCCGGGTTAGCTAGCCATGGCAAGC XmaI
prMS068 TCCCCCCGGGATGCCAAAGGCAAAAGCAAAAA XmaI
prMS069 CTAGTCTAGATTAGCTAGCCATGGCAAGC XbaI
prMS074 TCCCCCCGGGAAGCATGTTGCACTCCTCA XmaI
prMS075 CTAGTCTAGATTATTCGGCTTTTGGAGCTGTAA XbaI
prMS076 TCCCCCCGGG GAGCTTGAAAACACGCTCAT XmaI
prMS077 CTAGTCTAGATTAGCTGGCAATAGCAAGCG XbaI
prMS078 GGAATTCCATATGCAGCAATCGCATCAGGCTG NdeI
prMS083 TCCCCCCGGGGAATTAAAAAAAACACTCATCCC XmaI
prMS084 CTAGTCTAGATTAACTTGGCATAGGGACCTCTT XbaI
prMS090 TCCCCCCGGGTTACGAGGCCTGGCGTTCCACTGCGCCCA XmaI/StuI
prMS102 ACGCGTCGACCGATGAGCCATATGAAAAATATCAAA SalI
prMS103 TCCCCCCGGGTTAGCAAACTATTTTAGCTTGC XmaI
prMS104 AGCTTTGTTTAAACGATGAGCCATATGAAAAATATCAAA PmeI
prPG92 GGAATTCCATATGCCAAAGGCAAAAGCAAAAA NdeI
prPG93 GGAATTCCATATGTTAGCTAGCCATGGCAAGC NdeI
prPG095 GGAATTCCATATGTTAGCTGGCAATAGCAAGCG NdeI
prPG097 GGAATTCCATATGTTAGTTGGTAAGAGCCCTTG NdeI
prPG129 GGAATTCCATATGCCAAAAGCAAAAGCAAAAAA NdeI
prPG130 GGAATTCCATATGTTAGAGCATAATTATCTGTA NdeI
prRS167 TCCCCCCGGGTTAGCTAGCCATGGCAAGC XmaI
prRS180 ATGGTGTCGAAAGAATTAAAAAAAACACTCATCC SalI
prRS187 ATGGTGTCGACAAGAGTTAAAAAATATTCTCATTC SalI
prRS188 TCCCCCCGGGTTAGCTGGCTATAGCGAGTA XmaI
aRestriction endonuclease cleavage sites are underlined.
doi:10.1371/journal.ppat.0020115.t002
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HUVEC transfection. HUVECs were transfected using Amaxa
nucleofection technology (Amaxa, http://www.amaxa.com) following
the manufacturer’s guidelines for HUVEC transfection. After trans-
fection, cells were seeded into 24-well plates or six-well plates.
HEK293T cell transfection. Subconﬂuent (2.5 million cells)
HEK293T cells in 8-cm cell culture dishes were transfected with a
total of 2.5 lg DNA following the protocol ‘‘Calcium phosphate–
mediated transfection of eukaryotic cells with plasmid DNAs’’ [52].
After 12 h, the cell culture medium was replaced and the cells kept in
culture for an additional 24 h before ﬁxation for immunocytochem-
ical staining or harvesting for subcellular localization of the trans-
fected constructs.
Subcellular fractionation. Subcellular fractionation was performed
according to standard protocols [53,54]. Brieﬂy, conﬂuent mono-
layers were washed three times with cold homogenization buffer (10
mM triethanolamine, 10 mM acetic acid, 1 mM EDTA, 250 mM
sucrose [pH 7.4]), and cells were harvested by scraping and
homogenized with a syringe and a 22-gauge 1/4 inch needle. The
post-nuclear supernatant was obtained by centrifugation at 240g (15
min). Membranes were separated from cytosol by ultracentrifugation
of the post-nuclear supernatant at 100,000g (30 min).
Caspase activity assay. The infection of HUVECs and the
determination of caspase-3/-7 activity (MOI ¼ 300) were carried out
as described [12].
cya assay. cAMP was assayed after 20 h contact between bacteria
(MOI ¼ 300) and HUVECs in 24-well plates. HUVECs were washed
one time in pre-warmed PBS and lysed in denaturizing conditions as
described previously [19]. cAMP was assayed by an EIA system
(Biotrak; Amersham, http://www.amershambiosciences.com). Total
cell proteins were assayed by the method of Bradford [55] (Bradford
Reagent, Sigma-Aldrich).
CRAfT. The infection of the stably transfected Ea.hy926/pRS56-
c#B1 cell line and the quantiﬁcation of GFP-positive cells (percent
positive events) by ﬂow cytometry were carried out as described [13].
Immunoblot analysis. To monitor the steady-state level of Cya
fusion proteins, bacteria were grown on IPTG-containing medium
for 2 d. Cells were harvested and processed as described previously
[13], except that anti-FLAG M2 (Sigma-Aldrich) was used as the
primary antibody.
The stability of the different GFP fusion proteins used for ectopic
expression in HUVECs was monitored after transient transfection of
HEK293T cells. Cells were transfected by FuGENE 6 (Roche, http://
www.roche.com) following the manufacturer’s instructions. After 24 h
expression, cells were washed twice with PBS and harvested in 100 ll
of sample buffer. Samples were then further processed as described
before [13] and probed with anti-GFP (Roche) antibody.
Annexin V assay. Twenty-four hours after infection or transfection
of HUVECs, apoptosis was induced for 12–24 h. Cells were then
collected by mild trypsinization and brieﬂy centrifuged together with
the culture supernatant. The cell pellet was washed, resuspended, and
stained with PI (1 ug/ml) and Annexin V AlexaFluor488 (Molecular
Probes, http://probes.invitrogen.com) or Annexin V APC (Alexis,
http://www.axxora.com). The total apoptotic population was deter-
mined by analyzing Annexin V–positive and PI-negative/positive cells
with a FACSCalibur ﬂow cytometer (BD Biosciences, http://www.
bdbiosciences.com). Prior to determining the apoptotic population,
transfected cells were gated by their positive GFP signal.
Transfection and immunocytochemistry. HEK293T cells were
transfected for 30 h with different GFP-Bep fusion constructs, ﬁxed
with 3.7% paraformaldehyde, and immunocytochemically stained
with Texas Red–labeled WGA (Invitrogen, http://www.invitrogen.
com). Specimens were analyzed by confocal microscopy as described
[12].
Determination of IL-8 secretion. The infection (MOI ¼ 300) of
HUVECs and the determination of IL-8 secretion by IL-8 DuoSet
ELISA kit (R&D Systems, http://www.rndsystems.com) were performed
as described before [12].
Determination of intracellular cAMP level. After infection (MOI¼
150) of HUVECs for 30 h in 24-well plates, cells were washed with pre-
warmed PBS and lysed. Intracellular cAMP level was determined by
the EIA system (Biotrak, Amersham) as described by the manufac-
turer.
Real-time PCR. To quantify the activation of the cAMP pathway,
total cellular RNA was isolated at 54 h after infection as described
above. RNA manipulation and real-time PCR was performed as
previously described [56] using primers listed in Table 2.
Effects of exogenous cAMP and cAMP-elevating agents. HUVECs
were infected in the absence or presence of either forskolin (Sigma-
Aldrich) and IBMX (Sigma-Aldrich) or dibutyryl cAMP (Sigma-
Aldrich) for 24 h with the indicated Bh strains (MOI ¼ 300) or left
uninfected (control). Apoptosis was induced, and caspase-3/-7
activities were monitored as described above.
CTL assay upon infection. Conﬂuent HLA-A2-positive HUVEC (a
gift from B. C. Biedermann, Department of Research, University
Hospital Basel, Basel, Switzerland) monolayers were labeled with 5 lM
carboxyﬂuorescein diacetate, succinimidyl ester (CFSE, Molecular
Probes), in M199 without FCS according to the manufacturer’s
protocol. Cells were then infected with indicated Bh strains (MOI ¼
300) or left uninfected in M199/10% FCS/500 lM IPTG for 24 h. The
HLA-A2-restricted CTL clones speciﬁc to the Y-chromosome-
encoded, male-speciﬁc minor histocompatibility peptide antigen
SMCY were generated as described previously [32]. CTLs were washed
by centrifugation and were added in an effector-to-target cell ratio of
5:1 in replacing the infection medium with CTL assay medium (M199,
2% FCS, 500 lM IPTG). Plates were centrifuged to bring the cells in
contact. To quantify the surviving and dead cell rate, we used
Annexin V and PI staining and ﬂow cytometry (described above).
Prior to determining the surviving and dead cell populations, CFSE-
positive cells were gated by their positive GFP signal.
Supporting Information
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank) accession num-
bers for orthologous sequences to Bh BepA are Bq (NC 005955) and Bt
(CAD37389).
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